A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)

Inclusion criteria

• Clinically or pathologically diagnosed as hydatidiform mole.
• Availability of complete medical records, including clinical and pathological data.
• No evidence of myometrial invasion or metastasis.
• Serum hCG levels normalized after uterine evacuation with at least 6 months of follow-up, OR diagnosed with postmolar gestational trophoblastic neoplasia (pGTN) during follow-up.
• No history of psychiatric disorders, serious infectious diseases, or immune system diseases (such as systemic lupus erythematosus, myasthenia gravis, HIV infection, etc.).
• Willing to participate in this study and sign the relevant informed consent form.

Exclusion criteria

• Missing clinical data.
• Loss to follow-up: Do not return to participating hospital for follow-up visits after uterine evacuation, or could not be contacted for subsequent monitoring of hCG changes.
• Concomitant malignancies or autoimmune deficiency disorders (e.g., systemic lupus erythematosus, myasthenia gravis, HIV infection, etc.).
• As determined by the investigator, the presence of medical, psychological, social, occupational, or other conditions that would violate the study protocol or impair the subject's ability to provide informed consent.